Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation

@inproceedings{Sun2018GeneticPO,
  title={Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation},
  author={Chang Sun and Zhuojun Zhang and Jingbo Qie and Yi Wang and Ji Qian and Jiu-cun Wang and Junjie Wu and Qiang Hua Li and Chunxue Bai and Baohui Han and Zhiqiang Gao and Jibin Xu and Daru Lu and Li Jin and Haijian Wang},
  booktitle={Oncotarget},
  year={2018}
}
SLC31A1 is the major transporter for platinum drug intake, its expression correlates with drug disposition and response. In 1004 Chinese NSCLC patients with platinum-based chemotherapy, we investigated the association between SLC31A1 polymorphisms and clinical outcomes. Heterozygotes of rs10759637 at 3'UTR was associated with severe thrombocytopenia (odds ratio [OR]: 2.69; P = 0.012) and shorter overall survival (hazard ratio [HR]: 1.24; P = 0.005). Variant homozygote of rs2233914 was… CONTINUE READING
0 Citations
44 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Similar Papers

Loading similar papers…